Filter by year:

Filter by tags:


GTP and The Center for Breakthrough Medicines Partner in the Manufacturing of Gene Therapies

The University of Pennsylvania's Gene Therapy Program (GTP) and The Center for Breakthrough Medicines (CBM) have signed a landmark collaboration agreement to combine Penn's knowledge and expertise in the development of gene therapies with CBM's manufacturing capacity and singular focus on advanced therapies.


GTP Announces Expansion of R&D Partnership with Passage Bio

GTP announced the continued expansion of its R&D partnership with Passage Bio, a Penn spinout focused on developing transformative therapies for central nervous system disorders. Passage Bio exercised two additional options with GTP, which focused on CNS diseases with high unmet need.


GTP Expands Collaboration with Scout Bio Via Next-Generation Vector Technologies

The Gene Therapy Porgram (GTP) at the University of Pennsylvania announced an expanded collaboration agreement with Penn spinout, Scout Bio. The agreement will grant Scout Bio exclusive rights, in the field of animal health, to an emerging viral vector capsid technology for use in animal gene therapy, as well as extended option terms to other next-generation AAV vector technologies.


Dr. Jim Wilson Named one of the Top 20 Translational Researchers of 2020.

Dr. Jim Wilson, Director of the Gene Therapy Program (GTP) at the University of Pennsylvania, has been recognized by Nature Biotechnology as one of the Top 20 Translational Researchers of 2020.


GTP's Dr. Jim Wilson Delivers Special Lecture for USciences’ Bicentennial Celebration

Dr. Jim Wilson, Director of the Gene Therapy Program at the University of Pennsylvania, recently delivered a virtual lecture as a part of the University of the Sciences in Philadelphia's Bicentennial Symposium. Dr. Wilson's presentation, “The Potential of Gene Therapy for Human Monogenic Diseases," is available to view on-demand.


iECURE, co-founded by GTP's Dr. Jim Wilson, Launches With $50 Million Series A Financing to Develop In Vivo Gene Insertion Approaches for Devastating Diseases

iECURE, a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need, announced it has closed a $50 million Series A financing led by Versant Ventures and OrbiMed Advisors. The funds will be used to advance iECURE’s pipeline of up to 13 programs, all of which benefit from gene editing and in vivo delivery approaches being developed in the laboratory of James Wilson, M.D., Ph.D., of the University of Pennsylvania Gene Therapy Program (GTP).